E6 variants of human papillomavirus 18 differentially modulate the protein kinase B/phosphatidylinositol 3-kinase (akt/PI3K) signaling pathway

Virology

Volumn 383, Issue 1, 2009, Pages 78-85

  Contreras Paredes, Adriana ^a   De la Cruz Hernández, Erick ^a   Martínez Ramírez, Imelda ^a   Dueñas González, Alfonso ^a   Lizano, Marcela ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Akt PKB; E6; hDlg; HPV variants; MAPK; PI3K

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 14; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN E6; PROTEIN HUMAN DISC LARGE; PROTEIN KINASE B; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ANALYSIS; GENE SILENCING; HELA CELL; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; ISOLATION PROCEDURE; METHYLATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; PTERIDACEAE; WESTERN BLOTTING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CELL LINE; CELL PROLIFERATION; DNA-BINDING PROTEINS; GENE SILENCING; GENETIC VARIATION; HUMAN PAPILLOMAVIRUS 18; HUMANS; MEMBRANE PROTEINS; ONCOGENE PROTEINS, VIRAL; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS - 18;

EID: 57149116328     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2008.09.040     Document Type: Article

References (59)

1. Adey N.B., Huang L., Ormonde P.A., Baumgard M.L., Pero R., Byreddy D.V., Tavtigian S.V., and Bartel P.L. Threonine phosphorylation of the MMAC1/PTEN PDZ binding domain both inhibits and stimulates PDZ binding. Cancer Res. 60 (2000) 35-37
2. Bertelsen B.I., Steine S.J., Sandvei R., Molven A., and Laerum O.D. Molecular analysis of the PI3K-AKT pathway in uterine cervical neoplasia: frequent PIK3CA amplification and AKT phosphorylation. Int. J. Cancer 118 (2006) 1877-1883
3. Bosch F.X., Lorincz A., Munoz N., Meijer C.J., and Shah K.V. The causal relation between human papillomavirus and cervical cancer. J. Clin. Pathol. 55 (2002) 244-265
4. Chai B., Li J.Y., Zhang W., Ammori J.B., and Mulholland M.W. Melanocortin-3 receptor activates MAP kinase via PI3 kinase. Regul. Pept. 139 (2007) 115-121
5. Chakrabarti O., Veeraraghavalu K., Tergaonkar V., Liu T., Androphy E.J., Stanley M.A., and Krishna S. Human papillomavirus type 16 E6 amino acid 83 variants enhance E6-mediated MAPK signaling and differentially regulate tumorigenesis by notch signaling and oncogenic Res. J. Virol. 78 (2004) 5934-5945
6. Cheung T.H., Lo K.W., Yim S.F., Chan L.K., Heung M.S., Chan C.S., Cheung A.Y., Chung T.K., and Wong Y.F. Epigenetic and genetic alternation of PTEN in cervical neoplasm. Gynecol. Oncol. 93 (2004) 621-627
7. Dalstein V., Riethmuller D., Pretet J.L., Le Bail C.K., Sautiere J.L., Carbillet J.P., Kantelip B., Schaal J.P., and Mougin C. Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study. Int. J. Cancer 106 (2003) 396-403
8. De la Cruz E., Mohar A., Garcia-Carranca A., Dueñas A., Contreras-Paredes A., Pérez-Cárdenas E., Herrera R., and Lizano-Soberon M. Differential splicing of E6 within human papillomavirus type 18 variants and functional consequences. J. Gen.Virol. 86 (2005) 2459-2468
9. Donzé, O., Picard, D., 2002. RNA interference in mammalian cells using siRNAs synthesized with T7 RNA polymerase. Nucl. Ac. Res. 15, 30, e46.
10. Downward J. PI 3-kinase, Akt and cell survival. Semin. Cell Dev. Biol. 15 (2004) 177-182
11. Graness A., Adomeit A., Heinze R., Wetzker R., and Liebmann C.A. Novel mitogenic signaling pathway of bradykinin in the human colon carcinoma cell line SW-480 involves sequential activation of a Gq/11 protein, phosphatidylinositol 3-kinase beta, and protein kinase Cepsilon. J. Biol. Chem. 273 (1998) 32016-32022
12. Grm H.S., and Banks L. Degradation of hDlg and MAGIs by human papillomavirus E6 is E6-AP-independent. J. Gen. Virol. 85 (2004) 2815-2819
13. Haluska F.G., Tsao H., Wu H., Haluska E.S., Lazar A., and Goel V. Genetic alterations in signaling pathways in melanoma. Clin. Cancer Res. 12 (2006) 2301s-2307s
14. Harima Y., Sawada S., Nagata K., Sougawa M., Ostapenko V., and Ohnishi T. Mutation of the PTEN gene in advanced cervical cancer correlated with tumor progression and poor outcome after radiotherapy. Int. J. Oncol. 18 (2001) 493-497
15. Herman J.G., Graff J.R., Myohanen S., Nelkin B.D., and Baylin S.B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 9821-9826
16. Hildesheim A., Schiffman M., Bromley C., Wacholder S., Herrero R., Rodriguez A., Bratti M.C., Sherman M.E., Scarpidis U., Lin Q.Q., Terai M., Bromley R.L., Buetow K., Apple R.J., and Burk R.D. Human papillomavirus type 16 variants and risk of cervical cancer. J. Natl. Cancer Inst. 93 (2001) 315-318
17. Ishidate T., Matsumine A., Toyoshima K., and Akiyama T. The APC-hDLG complex negatively regulates cell cycle progression from the G0/G1 to S phase. Oncogene 19 (2000) 365-372
18. Jeong K.W., Kim H.Z., Kim S., Kim Y.S., and Choe J. Human papillomavirus type 16 E6 protein interacts with cystic fibrosis transmembrane regulator-associated ligand and promotes E6-associated protein-mediated ubiquitination and proteasomal degradation. Oncogene 26 (2007) 487-499
19. Jorda M.A., Vinyals A., Marazuela A., Cubillo E., Olmeda D., Valero E., Cano A., and Fabra A. Id-1 is induced in MDCK epithelial cells by activated Erk/MAPK pathway in response to expression of the Snail and E47 transcription factors. Exp. Cell. Res. 3 (2007) 2389-2403
20. Kammer C., Tommasino M.M., Syrjanen S., Delius H., Hebling U., Warthorst U., Pfister H., and Zehbe I. Variants of the long control region and the E6 oncogene in European human papillomavirus type 16 isolates: implications for cervical disease. Br. J. Cancer 86 (2002) 269-273
21. Knobbe C.B., and Reifenberger G. Genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-3′-kinase/protein kinase B (Akt) signal transduction pathway in glioblastomas. Brain Pathol. 13 (2003) 507-518
22. Kranenburg O., Verlaan I., Hordijk P.L., and Moolenaar W.H. Gi-mediated activation of the Ras/MAP kinase pathway involves a 100 kDa tyrosine-phosphorylated Grb2 SH3 binding protein, but not Src nor Shc. EMBO J. 16 (1997) 3097-3105
23. Kurose K., Zhou X.P., Araki T., and Eng C. Biallelic inactivating mutations and an occult germline mutation of PTEN in primary cervical carcinomas. Genes Chromosomes Cancer 29 (2000) 166-172
24. Laprise P., Viel A., and Rivard N. Human Homolog of Disc-large is required for Adherens junction assembly and differentiation of human intestinal Epithelial cells*. J. Biol. Chem. 279 (2004) 10166-19157
25. Lawlor M.A., and Alessi D.R. PKB/Akt: a key mediator of cell proliferation, survival and insulin responses. J. Cell Sci. 114 (2001) 2903-2910
26. Lee S.S., Weiss R.S., and Javier R.T. Binding of human virus oncoproteins to hDlg/SAP97, a mammalian homolog of the Drosophila discs large tumor suppressor protein. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 6670-6675
27. Lee J.S., Choi Y.D., Lee J.H., Nam J.H., Choi C., Lee M.C., Park C.S., Kim H.S., and Min K.W. Expression of PTEN in the progression of cervical neoplasia and its relation to tumor behavior and angiogenesis in invasive squamous cell carcinoma. J. Surg. Oncol. 93 (2006) 233-240
28. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S.L., Puc J., Miliaresis C., Rodgers L., McCombie R., Bigner S.H., Giovanella B.C., Ittmann M., Tycko B., Hibshoosh H., Wigler M.H., and Parsons R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275 (1997) 1943-1947
29. Lin H.T., Steller M.A., Aish L., Hanada T., and Chishti A.H. Differential expression of human Dlg in cervical intraepithelial neoplasias. Gynecol. Oncol. 93 (2004) 422-428
30. Lizano M., Berumen J., Guido M., Casas L., and Garcia-Carranca A. Association between human papillomavirus type 18 variants and histopathology of cervical cancer. J. Natl. Cancer Inst. 89 (1997) 1227-1231
31. Ma Y., Wei Y.S.J., Lin Y.C., Lung J.C., Chang T.C., Whang-Peng J., Liu J.M., Yang D.M., Yang W.K., and Shen C.Y. PIK3CA as an oncogene in cervical cancer. Oncogene 19 (2000) 2739-2744
32. Malanchi I., Accardi R., Diehl F., Smet A., Androphy E., Hoheisel J., and Tommasino M. Human papillomavirus type 16 E6 promotes retinoblastoma protein phosphorylation and cell cycle progression. J. Virol. 78 (2004) 13769-13778
33. Mantovani F., and Banks L. The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene 20 (2001) 7874-7887
34. Mantovani F., Massimi P., and Banks L. Proteasome-mediated regulation of the hDlg tumour suppressor protein. J. Cell. Sci. 114 (2001) 4285-4292
35. Massimi P., Gammoh N., Thomas M., and Banks L. HPV E6 specifically targets different cellular pools of its PDZ domain-containing tumour suppressor substrates for proteasome-mediated degradation. Oncogene 23 (2004) 8033-8039
36. Mei Q.i., Ann E., Anderson D.C., Shishinn S., and Auborn K.J. Indole-3-carbinol prevents PTEN loss in cervical cancer in vivo. Mol Med. 11 (2005) 59-63
37. Motoyama S., Ladines-Llave C.A., Villanueva L.S., and Maruo T. The role of human papilloma virus in the molecular biology of cervical carcinogenesis. Kobe J. Med. Sci. 50 (2004) 9-19
38. Nair P., Somasundaram K., and Krishna S. Activated Notch1 inhibits p53-induced apoptosis and sustains transformation by human papillomavirus type 16 E6 and E7 oncogenes through a PI3K-PKB/Akt-dependent pathway. J. Virol. 77 (2003) 7106-7112
39. Pedrero J.M., Carracedo D.G., Pinto C.M., Zapatero A.H., Rodríguez J.P., and Nieto C.S. Frequent genetic and biochemical alterations of the PI 3-K/AKT/PKB/PTEN pathway in head and neck squamous cell carcinoma. Int. J. Cancer 114 (2005) 242-248
40. Pim D., Massimi P., Dilworth S.M., and Banks L. Activation of the protein kinase B pathway by the HPV-16 E7 oncoprotein occurs through a mechanism involving interaction with PP2A. Oncogene 24 (2005) 7830-7838
41. Roymans D., and Slegers H. Phosphatidylinositol 3-kinases in tumor progression. Eur. J. Biochem. 268 (2001) 487-498
42. Sansal I., and Sellers W.R. The biology and clinical relevance of the PTEN Tumor suppressor Pathway. J. Clinical Oncol. 14 (2004) 2963-2964
43. Stoppler M.C., Ching K., Stoppler H., Clancy K., Schlegel R., and Icenogle J. Natural variants of the human papillomavirus type 16 E6 protein differ in their abilities to alter keratinocyte differentiation and to induce p53 degradation. J. Virol. 70 (1996) 6987-6993
44. Su T.H., Chang J.G., Perng I.l., Chang C.P., Wel H.J., Wang N.M., and Tsai C.H. Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in cervical cancer. Gynecol. Oncol. 76 (2000) 193-199
45. Sun S., and Steinberg B.M. PTEN is a negative regulator of STAT3 activation in human papillomavirus-infected cells. J. Gen. Virol. 83 (2002) 1651-1658
46. Tak-Hong C., Wing-Kit L.K., So-Fan Y., Kit-Ying L.C., Mei-Sze H., Chun-Sing C., Yu-Kiu A.C., Kwok-Hung T.C., and Yick-Fu W. Epigenetic and genetic alternation of PTEN in cervical neoplasm. Gynecol. Oncol. 93 (2004) 621-627
47. Tashiro H., Blazes M.S., Wu R., Cho K.R., Bose S., Wang S.L., Li J., Parsons R., and Ellenson L.H. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res. 57 (1997) 1940-3935
48. Thomas M., Glaunsinger B., Pim D., Javier R., and Banks L. HPV E6 and MAGUK protein interactions: determination of the molecular basis for specific protein recognition and degradation. Oncogene 20 (2001) 5431-5439
49. Tsugawa K., Jones M.K., Sugimachi K., Sarfeh I.J., and Taarnawski A.S. Biological role of phosphatase PTEN in cancer and tissue injury healing. Front. Biosci. 7e (2002) 245-251
50. Valiente M., Andres-Pons A., Gomar B., Torres J., Gil A., Tapparel C., Antonarakis S.E., and Pulido R. Binding of PTEN to specific PDZ domains contributes to PTEN protein stability and phosphorylation by microtubule-associated serine/threonine kinases. J. Biol. Chem. 280 (2005) 28936-28943
51. Watson R.A., Rollason G.T.P., Reynolds M., Murray P.G., Banks L., and Roberts S. Changes in expression of the human homologue of the Drosophila discs large tumour suppressor protein in high-grade premalignant cervical neoplasias. Carcinogenesis 23 (2002) 1791-1796
52. Wells V., Downward J., and Mallucci L. Functional inhibition of PI3K by the bGBP molecule suppresses Ras-MAPK signaling to block cell proliferation. Oncogene 26 (2007) 7709-7714
53. Wennstrom S., and Downward J. Role of phosphoinositide 3-kinase in activation of ras and mitogen-activated protein kinase by epidermal growth factor. Mol. Cell. Biol. 19 (1999) 4279-4288
54. Yaginuma Y., Yamashita T., Ishiya T., Morizaki A., Katoh Y., Takahashi T., Hayashi H., and Ishikawa M. Abnormal structure and expression of PTEN/MMAC1 gene in human uterine cancers. Mol. Carcinog. 27 (2000) 110-116
55. Yamato K., Fen J., Kobuchi H., Nasu Y., Yamada T., Nisishihara T., Ikeda Y., Kizaki M., and Yoshinouchi M. Induction of cell death in human papillomavirus 18-positive cervical cancer cells by E6 siRNA. Cancer Gene Ther. 13 (2006) 234-241
56. Yang H.J., Liu V.W., Wang Y., Tsang P.C., and Ngan H.Y. Differential DNA methylation profiles in gynecological cancers and correlation with clinico-pathological data. BMC Cancer 6 (2006) 212
57. Zhang Y., Dasgupta J., Ma R.Z., Bankuman S.L., Thomas M., and Chen X.S. Structures of a human Papillomavirus (HPV) E6 polypeptide bound MAGUK Proteins: mechanisms of targeting tumor suppressors by a high risk HPV oncoprotein. J. Virol. 81 (2007) 3618-3626
58. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev., Cancer 2 (2002) 342-350
59. Zysman M.A., Chapman W.B., and Bapat B. Considerations when analyzing the methylation status of PTEN tumor suppressor gene. Am. J. Pathol. 160 (2002) 795-800